<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-051029</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effectiveness and safety of imatinib in seven gastrointestinal stromal tumor cases</dc:title>
<dc:description xml:lang="en">Objective: To measure the effectiveness and safety of imatinibfor gstrointestinal stromal tumors (GISTs).Method: A retrospective study from 1993 through June 2005by identifying all patients diagnosed with GIST by the PathologyDepartment. The medical records of those treated with imatinibwere reviewed. Demographic, diagnostic, therapeutic, and outcome-related data were collected.Results: Twenty-five patients were identified, 7 of them treatedwith imatinib. Total responses were 4/7; 2/7 cases were completeresponses, and 2/7 were partial responses. Mean actuarialdisease-free survival was 10 months, and overall survival was 44months. Adverse reactions (ARs) reported included: 33% (5) gastrointestinalevents, 40% (6) dermatologic events and/or edema,14% (2) blood toxicity, and 13% (2) asthenia. In all, 2/7 patientsexperienced no imatinib-related toxicity.Conclusions: In our experience, imatinib is an effective, welltolerated therapy for malignant [c-Kit (CD117)-positive], nonresectableand/or metastatic GIST</dc:description>
<dc:creator>Grutzmancher Saiz, S</dc:creator>
<dc:creator>Sánchez Gómez, E</dc:creator>
<dc:creator>Giménez Castellanos, J</dc:creator>
<dc:creator>Gabella Bazarot, E</dc:creator>
<dc:creator>Marín Ariza, I</dc:creator>
<dc:creator>Reina Zoiló, J. J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Medir la efectividad y seguridad de imatinib en lostumores del estroma gastrointestinal (GIST).Método: Estudio retrospectivo desde el año 1993 hasta juniode 2005 donde se identificaron todos los pacientes diagnosticadosde GIST por anatomía patológica, y se revisaron historias clínicasde los tratados con imatinib. Se recogieron datos demográficos,relativos al diagnóstico, al tratamiento y a la evolución.Resultados: Se identificaron 25 pacientes, 7 tratados conimatinib. La respuesta total fue de 4/7, 2/7 casos fueron respuestascompletas y otros 2/7 respuestas parciales. La mediana actuarialde supervivencia libre de enfermedad alcanzada fue de 10meses y la global 44 meses. Las reacciones adversas (RAM) recogidasfueron: 33% (5) gastrointestinales, 40% (6) dermatológicasy/o edema, 14% (2) toxicidad hematológica y 13% (2) astenia. El2/7 pacientes no experimentaron ningún tipo de toxicidad relacionadacon imatinib.Conclusiones: En nuestra experiencia, imatinib constituye untratamiento efectivo y de buena tolerancia para el GIST maligno[c-Kit (CD117) positivo] no resecable y/o metastásico</dc:description>
<dc:source>Farm Hosp;30(4): 230-234, jul.-ago. 2006. tab</dc:source>
<dc:identifier>ibc-051029</dc:identifier>
<dc:title xml:lang="es">Efectividad y seguridad de imatinib en siete casos de tumores del estroma gastrointestinal</dc:title>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d11312^s22020</dc:subject>
<dc:subject>^d32281</dc:subject>
<dc:subject>^d11312^s22073</dc:subject>
<dc:subject>^d5911^s22057</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d974^s22073</dc:subject>
<dc:subject>^d12180^s22073</dc:subject>
<dc:subject>^d12180^s22020</dc:subject>
<dc:subject>^d9560</dc:subject>
<dc:type>article</dc:type>
<dc:date>200608</dc:date>
</metadata>
</record>
</ibecs-document>
